A PHASE 1/2, MULTI-CENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF ELOTUZUMAB(HUMANIZED ANTI-CS1 MONOCLONAL IGG1 ANTIBODY) AND BORTEZOMIB IN SUBJECTS WITH MULTIPLE MYELOMA FOLLOWING ONE TO THREE PRIOR THERAPIES.: